The role of carvedilol in the management of portal hypertension

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 8, 2010, Pages 905-911

  Tripathi, Dhiraj ^a   Hayes, Peter C ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

beta blockers; cirrhosis; hepatic venous pressure gradient; portal hypertension

Indexed keywords

CARVEDILOL; NEBIVOLOL; PROPRANOLOL; ANTIHYPERTENSIVE AGENT; BENZOPYRAN DERIVATIVE; CARBAZOLE DERIVATIVE; ETHANOLAMINE DERIVATIVE; NITRIC ACID DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ASCITES; BLEEDING; DRUG EFFICACY; DRUG TOLERABILITY; HEPATIC VEIN; HUMAN; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; REVIEW; VARIX BLEEDING; DRUG COMBINATION; DRUG EFFECTS; HEMODYNAMICS; HYPERTENSION, PORTAL; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIHYPERTENSIVE AGENTS; ASCITES; BENZOPYRANS; CARBAZOLES; DRUG THERAPY, COMBINATION; ETHANOLAMINES; HEMODYNAMICS; HUMANS; HYPERTENSION, PORTAL; MULTICENTER STUDIES AS TOPIC; NITRATES; PROPANOLAMINES; PROPRANOLOL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77955208253     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283367a99     Document Type: Review

References (38)

1. Damico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin Gastroenterol 1997; 11:243-256.
2. Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99:1401-1407.
3. Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346:1056-1059.
4. Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. Hepatology 1987; 7:648-653.
5. Lebrec D, Hillon P, Munoz C, Goldfarb G, Nouel O, Benhamou JP. The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology 1982; 2:523-527. (Pubitemid 13173931)
6. Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. Hepatology 1985; 5:97-101.
7. Lui HF, Stanley AJ, Forrest EH, Jalan R, Hislop WS, Mills PR, et al. Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 2002; 123:735-744.
8. Tripathi D, Graham C, Hayes PC. Variceal band ligation versus beta-blockers for primary prevention of variceal bleeding: a meta-analysis. Eur J Gastroenterol Hepatol 2007; 19:835-845.
9. Garcia-Pagan JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodes J. Enhancement of portal pressure reduction by the association of isosorbide- 5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology 1990; 11:230-238.
10. Merkel C, Sacerdoti D, Bolognesi M, Enzo E, Marin R, Bombonato G, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. Hepatology 1997; 26:34-39.
11. Bruha R, Vitek L, Petrtyl J, Lenicek M, Urbanek P, Zelenka J, et al. Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes. Scand J Gastroenterol 2006; 41:1454-1463. (Pubitemid 44764407)
12. Lin HC, Yang YY, Hou MC, Huang YT, Lee FY, Lee SD. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5- mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Am J Gastroenterol 2004; 99:1953-1958.
13. Banares R, Moitinho E, Matilla A, Garcia-Pagan JC, Lampreave JL, Piera C, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002; 36:1367-1373.
14. De BK, Das D, Sen S, Biswas PK, Mandal SK, Majumdar D, et al. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. J Gastroenterol Hepatol 2002; 17:183-189.
15. Tripathi D, Therapondos G, Lui HF, Stanley AJ, Hayes PC. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther 2002; 16:373-380.
16. Banares R, Moitinho E, Piqueras B, Casado M, Garcia-Pagan JC, De Diego A, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1- adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999; 30:79-83.
17. Stanley AJ, Therapondos G, Helmy A, Hayes PC. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol 1999; 30:479-484.
18. Sekiyama T, Komeichi H, Nagano T, Ohsuga M, Terada H, Katsuta Y, et al. Effects of the alpha-/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension. Arzneimittelforschung 1997; 47:353-355.
19. Forrest EH, Bouchier IA, Hayes PC. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. J Hepatol 1996; 25:909-915.
20. Silkauskaite V, Pranculis A, Kupcinskas J, Petrenkiene V, Kupcinskas L. Acute and 14-days hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis. A pilot study. J Hepatol 2009; 50:226.
21. Tripathi D, Ferguson JW, Kochar N, Leithead JA, Therapondos G, McAvoy NC, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 2009; 50:825-833.
22. Bartsch W, Sponer G, Strein K, Muller-Beckman B, von Mollendorf E, Abshagen U. Pharmakologie und klinische pharmakologie des neuen vasodila tierenden beta-rezeptoren blockers BM 14190. Therapiewoche 1982; 32:5714.
23. Abreu RM, Santos DJ, Moreno AJ. Effects of carvedilol and its analog BM-910228 on mitochondrial function and oxidative stress. J Pharmacol Exp Ther 2000; 295:1022-1030.
24. Akbas H, Ozden M, Kanko M, Maral H, Bulbul S, Yavuz S, et al. Protective antioxidant effects of carvedilol in a rat model of ischaemia-reperfusion injury. J Int Med Res 2005; 33:528-536. (Pubitemid 41388391)
25. Rolo AP, Oliveira PJ, Moreno AJ, Palmeira CM. Chenodeoxycholate induction of mitochondrial permeability transition pore is associated with increased membrane fluidity and cytochrome c release: protective role of carvedilol. Mitochondrion 2003; 2:305-311.
26. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227-2236.
27. Frishman WH. Carvedilol. N Engl J Med 1998; 339:1759-1765.
28. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994; 26:335-346.
29. Neugebauer G, Akpan W, Kaufmann B, Reiff K. Stereoselective disposition ofcarvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol 1990; 38 (Suppl 2):S108-S111.
30. Neugebauer G, Gabor M, Reiff K. Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction. J Cardiovasc Pharmacol 1992; 19 (Suppl 1): S142-S146.
31. Dulin B, Abraham WT. Pharmacology of carvedilol. Am J Cardiol 2004; 93:3B-6B.
32. Ohnishi K, Nakayama T, Saito M, Hatano H, Tsukamoto T, Terabayashi H, et al. Effects of propranolol on portal hemodynamics in patients with chronic liver disease. Am J Gastroenterol 1985; 80:132-135. (Pubitemid 15137209)
33. Mastai R, Bosch J, Navasa M, Kravetz D, Bruix J, Viola C, et al. Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. J Hepatol 1987; 4:71-79.
34. Albillos A, Lledo JL, Banares R, Rossi I, Iborra J, Calleja JL, et al. Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. Hepatology 1994; 20:611-617.
35. Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002; 50:571-581.
36. Lin HC, Huang YT, Wei HC, Yang YY, Lee TY, Wang YW, et al. Hemodynamic effects of one week of carvedilol administration on cirrhotic rats. J Gastroenterol 2006; 41:361-368.
37. Koshy A, Sekiyama T, Hadengue A, Cerini R, Braillon A, Lebrec D. Effects of alpha 1 and beta-adrenergic antagonists and 5-hydroxytryptamine receptor antagonist on portal-systemic collateral vascular resistance in conscious rats with portal hypertension. J Gastroenterol Hepatol 1992; 7:449-454.
38. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004; 39:280-282.